Rhabdomyosarcoma · 5 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
VA Variant #01 | — | R 55 254 | 84d | — | — | ~5 | ~R 166 548 indirect | — |
VAI Variant #02 | — | R 48 879 | 21d | — | — | ~3 | ~R 146 638 indirect | — |
VAC Variant #01 | — | R 28 321 | 7d | — | — | ~98 | ~R 131 693 indirect | — |
VIE Variant #01 | — | R 23 107 | 21d | — | — | ~3 | ~R 69 322 indirect | — |
VI, then VDC/IE, then VAC, then VI Partial | — | — | — | — | — | — | — | — |
5 of 5 regimens shown